ZOMETA® Case Study On How To Use ZOMETA® On a RCC Patient With Weaken Bone Destruction

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Renal Cell Carcinoma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study - Carlo

Carlo V.

Aged 67 years
Retired accountant
Takes sculpting classes twice a week

Page

1 2 3

In patients like Carlo, the vicious cycle of bone destruction is ongoing

Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction^6,7

Because bone is constantly being attacked even when the primary tumour is in remission, ZOMETA^® should be dosed every 3 to 4 weeks^6,8

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

In patients like Carlo, the vicious cycle of bone destruction is ongoing Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction6,7

Because bone is constantly being attacked even when the primary tumour is in remission, ZOMETA® should be dosed every 3 to 4 weeks6,8

In patients like Carlo, the vicious cycle of bone destruction is ongoing

Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction^6,7

Because bone is constantly being attacked even when the primary tumour is in remission, ZOMETA^® should be dosed every 3 to 4 weeks^6,8